APA (7th ed.) Citation

V, P., RL, C., AR, H., P, S., MA, P., TJ, H., & BM, S. (2026). Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(3), 447. https://doi.org/10.1158/1078-0432.CCR-25-2819

Chicago Style (17th ed.) Citation

V, Podder, Coleman RL, Hagemann AR, Singhania P, Powell MA, Herzog TJ, and Slomovitz BM. "Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 32, no. 3 (2026): 447. https://doi.org/10.1158/1078-0432.CCR-25-2819.

MLA (9th ed.) Citation

V, Podder, et al. "Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 32, no. 3, 2026, p. 447, https://doi.org/10.1158/1078-0432.CCR-25-2819.